In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...
Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...
Shares in US biotech Arvinas were more than 50% lower, and those in pharma giant Pfizer down 2%, at the mid-point of ...
The latest biotech to emerge from the Flagship Pioneering incubator – Lila Sciences – has emerged with $200 million in seed ...
Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...
Apnimed, Inc., a pharmaceutical company focused on discovering, developing, and commercializing first-in-class oral therapies for the neuromuscular dysfunction associated with obstructive sleep apnea ...
US pharma giant Pfizer (NYSE: PFE) today announced that James List, has joined the company as chief internal medicine officer ...
Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dolsten, who served as Pfizer’s chief scientific officer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback